ASPI vs ATI vs EMN Stock Comparison

ASP Isotopes, Ati and Eastman Chemical Prices as of Nov 13, 2026 Peers: Industry group
ASPI ASP Isotopes Inc.
$1.74 -15.9% 1M -78.3% 1Y
Market cap
$193.89M
P/E
–
Revenue (TTM)
$30.85M
Div. yield
–
Specialty Chemicals Basic Materials
1 win
ATI Ati Inc
$183.11 -2.5% 1M +85.8% 1Y
Market cap
$24.29B
P/E
43.7x
Revenue (TTM)
$5.01B
Div. yield
–
Specialty Chemicals Basic Materials
7 wins
EMN Eastman Chemical Co
$65.05 +3.4% 1M +3.7% 1Y
Market cap
$7.32B
P/E
8.0x
Revenue (TTM)
$9.05B
Div. yield
–
Specialty Chemicals Basic Materials
3 wins

Head to Head

11 decided of 12

Ati leads on 7 of the 12 questions below (Ati 7, Eastman Chemical 3, ASP Isotopes 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionASPIATIEMNLeader
Larger companyMarket capitalisation $193.89M $24.29B $7.32B ATI
Cheaper on earningsLower P/E, profitable companies only -1.7x 43.7x 8.0x EMN
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 37.8x 10.2x EMN
Faster revenue growthRevenue growth, trailing twelve months +573.4% +9.4% +0.3% ASPI
More profitableNet margin, trailing twelve months -380.3% 11.1% 10.1% ATI
Better return on capitalReturn on invested capital -28.6% 16.5% 7.3% ATI
Less leveragedLower net debt / EBITDA 2.1x 1.4x 3.2x ATI
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -78.3% +85.8% +3.7% ATI
Better 5-year returnAnnualised price return, 5 years — +60.5%/yr -10.9%/yr ATI
Less volatileAnnualised volatility, 1 year 99.0% 43.5% 31.6% EMN
Higher overall scoreMean of the five percentile scores vs peers 24/100 60/100 59/100 ATI

Percentile Scorecard

ASPIATIEMN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisASPIATIEMN
Valuation 11 #86 of 96 18 #79 of 96 85 #15 of 96
Growth 11 #82 of 92 80 #19 of 92 22 #72 of 92
Profitability 9 #81 of 89 88 #12 of 89 64 #33 of 89
Financial Health 66 #33 of 96 55 #44 of 96 32 #66 of 96
Shareholder Returns – 62 #31 of 79 94 #6 of 79
Overall 24 60 59
  • ASPI ranked among 99 companies in Chemicals
  • ATI ranked among 99 companies in Chemicals
  • EMN ranked among 99 companies in Chemicals

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodASPIATIEMNSPY
1 month -15.9%-2.5%+3.4% -2.0%
3 months -59.3%-19.9%-12.2% -2.8%
6 months -70.0%+18.7%-9.1% +2.0%
Year to date -67.5%+59.6%+1.9% +10.6%
1 year -78.3%+85.8%+3.7% +12.2%
3 years +14.5%+303.6%-18.5% +68.1%
3 years, per year +4.6%+59.3%-6.6% +18.9%
5 years —+963.4%-43.9% +61.4%
5 years, per year —+60.5%-10.9% +10.1%
10 years —+977.8%-13.5% +248.5%
10 years, per year —+26.8%-1.4% +13.3%

Risk

MeasureASPIATIEMNSPY
Volatility, 1Y 99.0%43.5%31.6% 13.6%
Downside volatility, 1Y 98.1%42.8%29.8% 13.9%
Beta vs S&P 500, 1Y 3.631.660.87 1.00
Return / volatility, 1Y -0.791.970.12 0.90
Max drawdown, 5Y -88.6%-38.0%-55.9% -25.4%
From 52-week high -79.5%-21.0%-20.0% -3.2%
52-week high $8.48$231.79$81.36 $779.14
52-week low $1.72$94.80$56.37 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleASPIATIEMN
P/E now vs peer median -1.8xmedian 23.4x 44.9xmedian 23.4x 8.1xmedian 23.4x
P/S now vs peer median 7.3xmedian 1.3x 5.0xmedian 1.3x 0.8xmedian 1.3x
EV/EBITDA now vs peer median -0.3xmedian 12.7x 26.2xmedian 12.7x 8.5xmedian 12.7x
P/FCF now vs peer median -2.7xmedian 17.0x 59.1xmedian 17.0x 15.9xmedian 17.0x
P/B now vs peer median 0.8xmedian 1.5x 11.7xmedian 1.5x 1.2xmedian 1.5x
PEG now vs peer median 0.05median 1.72 3.38median 1.72 -13.19median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsASPIATIEMN
Revenue $30.85M $5.01B $9.05B
Gross profit $5.65M $1.23B $1.86B
Operating income -$99.07M $826.30M $868.00M
Net income -$117.34M $568.60M $627.00M
Free cash flow -$83.58M $421.10M $469.00M
R&D $22.04M – $246.00M
EPS (diluted) $-0.96 $4.01 $7.93
Cash & equivalents $219.60M $442.30M $768.00M
Total debt $59.77M $1.86B $5.22B
Shares (diluted) 122.72M 138.40M 115.30M
Enterprise value -$792.81M $22.25B $4.63B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricASPIATIEMN
P/E -1.8x 44.9x 8.1x
P/FCF -2.7x 59.1x 15.9x
P/Operating cash flow -3.3x 34.1x 8.5x
P/S 7.3x 5.0x 0.8x
P/B 0.8x 11.7x 1.2x
P/Tangible book 0.8x 11.7x 1.4x
EV/EBITDA -0.3x 26.2x 8.5x
EV/EBIT -0.3x 31.8x 13.7x
EV/Revenue 1.0x 5.2x 1.3x
EV/FCF -0.4x 62.4x 25.4x
EV/Operating cash flow -0.5x 36.0x 13.5x
PEG (3Y EPS CAGR) 0.05 3.38 -13.19

Growth

14 metrics
MetricASPIATIEMN
Revenue growth (1Y) 573.4% 9.4% 0.3%
Revenue CAGR (3Y) 2,420% 6.8% -1.2%
Gross profit growth (1Y) 214.3% 24.9% -9.7%
Gross profit CAGR (3Y) – 16.1% -1.9%
Operating income growth (1Y) -200.2% 21.7% -18.2%
Operating income CAGR (3Y) -105.1% 21.0% -1.2%
Net income growth (1Y) -17.1% 23.6% -13.3%
Net income CAGR (3Y) -119.1% 9.9% 2.2%
EPS growth (1Y) 30.3% 26.8% -17.2%
EPS CAGR (3Y) -37.1% 13.3% -0.6%
Operating cash flow growth (1Y) -244.7% 7.5% -12.8%
Operating cash flow CAGR (3Y) -151.6% – -13.9%
Free cash flow growth (1Y) -182.5% -5.2% 18.7%
Free cash flow CAGR (3Y) -123.3% – -3.8%

Profitability

14 metrics
MetricASPIATIEMN
Gross margin 18.3% 24.5% 20.6%
EBITDA margin -303.3% 20.0% 15.4%
Operating margin -321.1% 16.5% 9.6%
Pretax margin -443.4% 13.9% 7.2%
Net margin -380.3% 11.1% 10.1%
FCF margin -270.9% 8.4% 5.2%
Operating cash flow margin -219.8% 14.6% 9.7%
Return on equity -40.9% 27.5% 10.0%
Return on assets -20.2% 10.1% 4.1%
Return on invested capital -28.6% 16.5% 7.3%
Return on capital employed -19.4% 18.1% 6.8%
Asset turnover 0.1x 0.9x 0.6x
Cash conversion (OCF / net income) 0.6x 1.3x 1.4x
Stock comp / revenue 60.5% 0.6% –

Financial Health

11 metrics
MetricASPIATIEMN
Debt / assets 10.4% 33.4% 33.7%
Debt / equity 0.2x 0.9x 0.8x
Net debt / EBITDA 2.1x 1.4x 3.2x
Debt / FCF -0.7x 4.4x 11.1x
Liabilities / assets 52.0% 61.7% 59.0%
Equity / assets 48.0% 38.3% 41.0%
Interest coverage -25.3x 3.4x –
Current ratio 3.9x 2.8x 1.6x
Quick ratio 3.7x 1.2x 0.8x
Cash ratio 3.6x 0.4x 0.3x
Altman Z-score -0.30 6.39 2.32

Shareholder Returns

7 metrics
MetricASPIATIEMN
Dividend yield – – 5.2%
Net buyback yield -119.4% 0.8% –
Shareholder yield -119.4% 0.8% 5.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusASPIATIEMN
Forward P/E – 37.8xFY2026 10.2xFY2026
EPS, next fiscal year $-0.45FY2026 $4.85FY2026 $6.39FY2026
EPS growth, next FY – +49.7%FY2026 +17.9%FY2026
EPS growth, the year after – +25.8% -4.2%
Revenue, next fiscal year $24.34MFY2026 $5.34BFY2026 $9.46BFY2026
Revenue growth, next FY +2.0%FY2026 +16.4%FY2026 +8.2%FY2026
Revenue growth, the year after +189.0% +13.9% -3.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersASPIATIEMN
Held by institutions 50.3% 93.5% 94.1%
Institutions holding 189 788 651
Change in shares held, QoQ +3.3% +0.9% -0.1%
Institutions buying 114 481 327
Institutions selling 53 217 196
Buyers to sellers 2.15 2.22 1.67

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ASPIATIEMN
ASPI 1.00 0.38 0.21
ATI 0.38 1.00 0.22
EMN 0.21 0.22 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ASPI, ATI and EMN?

Ati (ATI) is the largest by market capitalisation: ASP Isotopes (ASPI) $193.89M, Ati (ATI) $24.29B, Eastman Chemical (EMN) $7.32B.

Which stock is cheaper, ASPI, ATI and EMN?

Eastman Chemical (EMN) trades on the lowest price-to-earnings ratio (ASP Isotopes (ASPI) -1.7x, Ati (ATI) 43.7x, Eastman Chemical (EMN) 8.0x). On next year's consensus earnings, Eastman Chemical (EMN) is cheapest (Ati (ATI) 37.8x, Eastman Chemical (EMN) 10.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

ASP Isotopes (ASPI) grew revenue fastest over the trailing twelve months: ASP Isotopes (ASPI) +573.4%, Ati (ATI) +9.4%, Eastman Chemical (EMN) +0.3%.

Which company is more profitable?

Ati (ATI) has the highest net margin (ASP Isotopes (ASPI) -380.3%, Ati (ATI) 11.1%, Eastman Chemical (EMN) 10.1%). On return on invested capital, Ati (ATI) leads (ASP Isotopes (ASPI) -28.6%, Ati (ATI) 16.5%, Eastman Chemical (EMN) 7.3%).

Which stock has performed better?

Over the past year Ati (ATI) returned the most: ASP Isotopes (ASPI) -78.3%, Ati (ATI) +85.8%, Eastman Chemical (EMN) +3.7%. Over five years, Ati (ATI) compounded fastest (Ati (ATI) +60.5%/yr, Eastman Chemical (EMN) -10.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Eastman Chemical (EMN) has been the steadiest (ASP Isotopes (ASPI) 99.0%, Ati (ATI) 43.5%, Eastman Chemical (EMN) 31.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ASPI, ATI and EMN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Ati (ATI) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.